Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study

Abstract Properly conducted serological survey can help determine infection disease true spread. This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias. A sample of adults was recruited with random digit dialling, intervie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anton Barchuk, Dmitriy Skougarevskiy, Kirill Titaev, Daniil Shirokov, Yulia Raskina, Anastasia Novkunkskaya, Petr Talantov, Artur Isaev, Ekaterina Pomerantseva, Svetlana Zhikrivetskaya, Lubov Barabanova, Vadim Volkov
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e34d17c9560d42279bea2488e7586880
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e34d17c9560d42279bea2488e7586880
record_format	dspace
spelling	oai:doaj.org-article:e34d17c9560d42279bea2488e75868802021-12-02T16:05:53ZSeroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study10.1038/s41598-021-92206-y2045-2322https://doaj.org/article/e34d17c9560d42279bea2488e75868802021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92206-yhttps://doaj.org/toc/2045-2322Abstract Properly conducted serological survey can help determine infection disease true spread. This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias. A sample of adults was recruited with random digit dialling, interviewed and invited for anti-SARS-CoV-2 antibodies. The seroprevalence was corrected with the aid of the bivariate probit model that jointly estimated individual propensity to agree to participate in the survey and seropositivity. 66,250 individuals were contacted, 6,440 adults agreed to be interviewed and blood samples were obtained from 1,038 participants between May 27 and June 26, 2020. Naïve seroprevalence corrected for test characteristics was 9.0% (7.2–10.8) by CMIA and 10.5% (8.6–12.4) by ELISA. Correction for non-response decreased estimates to 7.4% (5.7–9.2) and 9.1% (7.2–10.9) for CMIA and ELISA, respectively. The most pronounced decrease in bias-corrected seroprevalence was attributed to the history of any illnesses in the past 3 months and COVID-19 testing. Seroconversion was negatively associated with smoking status, self-reported history of allergies and changes in hand-washing habits. These results suggest that even low estimates of seroprevalence can be an overestimation. Serosurvey design should attempt to identify characteristics that are associated both with participation and seropositivity.Anton BarchukDmitriy SkougarevskiyKirill TitaevDaniil ShirokovYulia RaskinaAnastasia NovkunkskayaPetr TalantovArtur IsaevEkaterina PomerantsevaSvetlana ZhikrivetskayaLubov BarabanovaVadim VolkovNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anton Barchuk Dmitriy Skougarevskiy Kirill Titaev Daniil Shirokov Yulia Raskina Anastasia Novkunkskaya Petr Talantov Artur Isaev Ekaterina Pomerantseva Svetlana Zhikrivetskaya Lubov Barabanova Vadim Volkov Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
description	Abstract Properly conducted serological survey can help determine infection disease true spread. This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias. A sample of adults was recruited with random digit dialling, interviewed and invited for anti-SARS-CoV-2 antibodies. The seroprevalence was corrected with the aid of the bivariate probit model that jointly estimated individual propensity to agree to participate in the survey and seropositivity. 66,250 individuals were contacted, 6,440 adults agreed to be interviewed and blood samples were obtained from 1,038 participants between May 27 and June 26, 2020. Naïve seroprevalence corrected for test characteristics was 9.0% (7.2–10.8) by CMIA and 10.5% (8.6–12.4) by ELISA. Correction for non-response decreased estimates to 7.4% (5.7–9.2) and 9.1% (7.2–10.9) for CMIA and ELISA, respectively. The most pronounced decrease in bias-corrected seroprevalence was attributed to the history of any illnesses in the past 3 months and COVID-19 testing. Seroconversion was negatively associated with smoking status, self-reported history of allergies and changes in hand-washing habits. These results suggest that even low estimates of seroprevalence can be an overestimation. Serosurvey design should attempt to identify characteristics that are associated both with participation and seropositivity.
format	article
author	Anton Barchuk Dmitriy Skougarevskiy Kirill Titaev Daniil Shirokov Yulia Raskina Anastasia Novkunkskaya Petr Talantov Artur Isaev Ekaterina Pomerantseva Svetlana Zhikrivetskaya Lubov Barabanova Vadim Volkov
author_facet	Anton Barchuk Dmitriy Skougarevskiy Kirill Titaev Daniil Shirokov Yulia Raskina Anastasia Novkunkskaya Petr Talantov Artur Isaev Ekaterina Pomerantseva Svetlana Zhikrivetskaya Lubov Barabanova Vadim Volkov
author_sort	Anton Barchuk
title	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
title_short	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
title_full	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
title_fullStr	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
title_full_unstemmed	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
title_sort	seroprevalence of sars-cov-2 antibodies in saint petersburg, russia: a population-based study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e34d17c9560d42279bea2488e7586880
work_keys_str_mv	AT antonbarchuk seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT dmitriyskougarevskiy seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT kirilltitaev seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT daniilshirokov seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT yuliaraskina seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT anastasianovkunkskaya seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT petrtalantov seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT arturisaev seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT ekaterinapomerantseva seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT svetlanazhikrivetskaya seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT lubovbarabanova seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy AT vadimvolkov seroprevalenceofsarscov2antibodiesinsaintpetersburgrussiaapopulationbasedstudy
_version_	1718385180526247936

Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study

Ejemplares similares